Type 2 diabetes mellitus:: epidemiology, pathophysiology, unmet needs and therapeutical perspectives

被引:73
|
作者
Virally, M.
Blickle, J.-F.
Girard, J.
Halimi, S.
Simon, D.
Guillausseau, P.-J.
机构
[1] Univ Denis Diderot Paris 7, Hop Lariboisiere, Med Serv B, APHP, F-75010 Paris, France
[2] Hop Univ Strasbourg, Serv Med Interne, F-67091 Strasbourg, France
[3] Univ Paris 05, Inst Cochin, INSERM U567, CNRS UMR,Dept Endocrinol Met & Canc, F-75014 Paris, France
[4] CHU Grenoble, Serv Endocrinol Diabetol & Nutr, F-38043 Grenoble, France
[5] Hop La Pitie Salpetriere, Serv Diabetol, APHP, F-75013 Paris, France
[6] Univ Paris 06, F-75006 Paris, France
[7] INSERM, U780, F-94817 Villejuif, France
关键词
DPP-IV inhibitors; epidemiology; France; glinides; GLP1; analogues; metformin; obesity; pathogenesis; sulfonylureas; review; treatment antidiabetic oral agents; type 2 diabetes mellitus;
D O I
10.1016/j.diabet.2007.07.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In France, prevalence of drug-treated diabetes reached 3.60% in 2005, with 92% of type 2 diabetic patients. In 2007, there are probably nearly 3 000 000 diagnosed or undiagnosed diabetic patients. Ageing of the population and increase in obesity are the main causes of this "diabetes epidemic". Type 2 diabetes is a multifactorial disease, defined as resulting from defects in insulin secretion (including abnormalities in pulsatility and kinetics, quantitative and qualitative abnormalities of insulin, beta-cell loss progressing with time) associated with insulin resistance (affecting liver, and skeletal muscle) and increased glucagon secretion. The lack of compensation of insulin resistance by augmented insulin secretion results in rise in blood glucose. To achieve satisfactory glycaemic control in order. to prevent diabetes related complications, drug therapy is generally required in addition to life style changes. Currently available oral therapies offer a large panel of complementary drugs, but they have several contraindications and side effects. In spite of major advances in the management of type 2 diabetes, and the strictness of new guidelines, some goals remain unachieved and the new family of insulin-secretors (DPP-IV inhibitors, GLP-1 analogues) should enrich therapeutic approaches. (C) 2007 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:231 / 244
页数:14
相关论文
共 50 条